8-K: Ikena Oncology Stockholders Approve Merger with Inmagene Biopharmaceuticals, Paving Way for ImageneBio and 1-for-12 Reverse Stock Split

Ikena Oncology, Inc. stockholders have overwhelmingly approved all key proposals, including the merger with Inmagene Biopharmaceuticals and a 1-for-12 reverse stock split, setting the stage for the combined entity, ImageneBio, Inc., to trade on Nasdaq under the ticker IMA.

Summary

• Ikena Oncology, Inc. stockholders approved all proposals at the Annual Meeting on July 15, 2025, including the merger with Inmagene Biopharmaceuticals and a concurrent financing.
• Stockholders approved an amendment to the Ikena Charter to effect a reverse stock split at a ratio between 1:5 and 1:15, with the board subsequently approving a 1-for-12 ratio.
• The reverse stock split is expected to reduce outstanding Ikena common stock from approximately 48.2 million shares to approximately 4 million shares, prior to shares issued in connection with the merger.
• Approval was granted for the 2025 Equity Incentive Plan, which will initially reserve shares equal to 10% of the Combined Company's capital stock outstanding on its effective date, plus certain shares from the 2021 plan, with annual increases of 5% of outstanding common stock from 2026 to 2035.
• The 2025 Employee Stock Purchase Plan (ESPP) was also approved, reserving 1% of the Combined Company's capital stock initially, with annual increases of the lesser of 1% or 227,944 shares from 2026 to 2035.
• The merger and concurrent financing are anticipated to be consummated around the end of July 2025, subject to closing conditions.
• Following the merger and reverse stock split, the combined company will be named ImageneBio, Inc. and trade on Nasdaq under the new ticker symbol IMA with a new CUSIP number (45175G 207).

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. All key proposals for the merger and strategic restructuring were approved by stockholders, which is crucial for the transaction's completion. The combined entity will have a clinical-stage asset with promising Phase 2a results. However, the significant 'against' votes for the merger and reverse split, along with the inherent risks of biotech development and integration, temper the overall positive outlook.

Positives

• Stockholder approval of the merger with Inmagene Biopharmaceuticals and the concurrent financing provides a clear path for the strategic combination.
• The approval of the 1-for-12 reverse stock split is a necessary step to meet Nasdaq listing requirements for the combined entity.
• The approval of the 2025 Equity Incentive Plan and 2025 Employee Stock Purchase Plan provides a framework for attracting and retaining talent in the combined company.
• Inmagene's lead asset, IMG-007, a non-depleting anti-OX40 mAb, has completed Phase 2a clinical trials in atopic dermatitis and alopecia areata, showing sustained clinical and pharmacodynamic activity and good tolerability, strengthening the combined company's pipeline.

Negatives

• A significant number of stockholders voted against Proposal No. 1 (Merger and Concurrent Financing Share Issuance) with 17,001,465 votes against compared to 18,201,052 for, indicating a notable dissent.
• Similarly, Proposal No. 2 (Reverse Stock Split) saw 17,204,866 votes against compared to 21,026,179 for, suggesting considerable opposition to the reverse split.
• The reverse stock split, while necessary for listing, often signals a low stock price and can be perceived negatively by some investors.

Risks

• The risk that the conditions to the closing of the Merger are not satisfied or that one of the parties terminates the Merger Agreement.
• Uncertainties as to the timing of the consummation of the Merger and its ability to list the shares of the Combined Company on Nasdaq.
• Uncertainties as to the timing or consummation of the Reverse Stock Split.
• The risk that as a result of adjustments to the exchange ratio, Ikena stockholders and Inmagene shareholders could own more or less of the Combined Company than currently anticipated.
• Risks related to the market price of Ikena common stock relative to the value suggested by the exchange ratio.
• Unexpected costs, charges, or expenses resulting from the transaction.
• Potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed Merger and Reverse Stock Split.
• Uncertainties associated with Inmagene's platform technologies, as well as risks associated with the clinical development and regulatory approval of product candidates, including potential delays in the commencement, enrollment, and completion of clinical trials.
• Risks related to the inability of the Combined Company to obtain sufficient additional capital to continue to advance product candidates and preclinical programs.
• Uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom.
• Risks related to the failure to realize any value from product candidates and preclinical programs being developed.
• Risks associated with the possible failure to realize certain anticipated benefits of the proposed Merger, including with respect to future financial and operating results.
• The risk that the Ikena concurrent financing is not consummated.
• The possibility that contingent value rights holders of Ikena and Inmagene may never receive any proceeds pursuant to their respective contingent value rights agreements.

Future Outlook

The combined company, ImageneBio, Inc., is expected to commence trading on Nasdaq under the ticker symbol IMA around the end of July 2025, following the consummation of the merger and the 1-for-12 reverse stock split. The new entity will focus on developing novel therapeutics for immunological and inflammatory diseases, leveraging Inmagene's lead asset, IMG-007, which has completed Phase 2a clinical trials.

Management Comments

• Ikena expects to file a certificate of amendment to the Ikena Charter with the Secretary of State of the State of Delaware to effect the Reverse Stock Split prior to the closing of the Merger.
• The Combined Company's common stock is expected to commence trading on a split-adjusted, post-Merger basis on Nasdaq under the name ImageneBio, Inc. and ticker symbol IMA around the end of July.

Industry Context

This merger represents a strategic pivot for Ikena Oncology, shifting its primary focus from cancer therapies to immunological and inflammatory (I&I) diseases through the acquisition of Inmagene Biopharmaceuticals. This move aligns with a broader industry trend of consolidation and pipeline diversification, particularly in the competitive I&I therapeutic area, which continues to attract significant investment due to high unmet medical needs and large market potential. The combination aims to create a stronger, more focused entity with a clinical-stage asset (IMG-007) that has shown promise in early trials.

Comparison to Industry Standards

• The completion of Phase 2a clinical trials for IMG-007 in atopic dermatitis and alopecia areata is a standard and critical milestone in drug development, indicating progression through early human efficacy and safety assessment.
• IMG-007's profile as a humanized, subcutaneously administered, non-depleting IgG1 monoclonal antibody targeting OX40, with a silenced ADCC function and extended half-life (34.7 days), positions it competitively against other I&I therapies by potentially offering infrequent and convenient dosing, a key differentiator in patient adherence and market appeal.
• The reported tolerability of IMG-007, with no cases of pyrexia or chills, is a positive safety signal compared to some other biologic therapies that may have more pronounced side effect profiles.
• The strategic merger and reverse stock split are common corporate actions in the biotech sector, often undertaken by smaller companies to enhance financial stability, meet listing requirements, and combine complementary pipelines to achieve greater scale and attract investment, similar to recent consolidations seen among emerging biopharma firms.

Management Changes

Corporate Governance

Stakeholder Impact

• **Shareholders**: Will experience a 1-for-12 reverse stock split, reducing their number of shares but increasing the per-share price. Their ownership percentage in the combined company will be adjusted based on the merger exchange ratio and concurrent financing. They will also be subject to the terms of the new equity incentive and employee stock purchase plans.
• **Employees**: Will benefit from the new 2025 Equity Incentive Plan and 2025 Employee Stock Purchase Plan, providing opportunities for equity compensation and stock ownership, which can enhance retention and motivation.
• **Customers/Patients**: The merger aims to accelerate the development of novel therapeutics for immunological and inflammatory diseases, potentially bringing new treatment options to patients, particularly with IMG-007.
• **Creditors**: The merger and concurrent financing could impact the combined company's financial structure and liquidity, potentially affecting its credit profile, though no specific details on debt or credit impact are provided.
• **Management**: The approval of the merger and new equity plans provides a clear strategic direction and tools for incentivizing leadership and key personnel in the combined entity.

Next Steps

• Ikena expects to file a certificate of amendment to the Ikena Charter with the Secretary of State of the State of Delaware to effect the Reverse Stock Split.
• Consummation of the Merger and the Ikena concurrent financing around the end of July 2025.
• The Combined Company's common stock is expected to commence trading on a split-adjusted, post-Merger basis on Nasdaq under the name ImageneBio, Inc. and ticker symbol IMA around the end of July.
• The new CUSIP number (45175G 207) for the combined company's common stock will become effective.

Key Dates

Recommendation

Keywords

Ikena Oncology, Inmagene Biopharmaceuticals, Merger, Reverse Stock Split, Equity Incentive Plan, Employee Stock Purchase Plan, Biotechnology, Oncology, Immunological Diseases, Inflammatory Diseases, IMG-007, Nasdaq Listing, Corporate Governance, SEC Filing, 8-K